Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Daxor Corp. (DXR) Anemia Diagnostic Test Results featured in Congestive Heart Failure Publication

Daxor Crop., a medical instrumentation and biotechnology company, today announced the publication of a research article titled “Blood Volume Measurements in Patients with Heart Failure and a Preserved Ejection Fraction: Implications for Diagnosing Anemia” in the journal Congestive Heart Failure, which highlights a study using Daxor’s Volume Analyzer (BVA-100).

Anemia, or low red blood cell count, is often found in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). Anemia is traditionally diagnosed by measuring hemoglobin levels in a standard blood test, though patients with heart failure are harder to diagnose because of blood volume distortions, which can lead to overdiagnosis.

Daxor’s BVA-100 precisely measured the red blood cell volume in 60 patients with heart failure and a preserved ejection fraction. The results were compared to ideal red blood cell volume for each patient as measured by the standard method of diagnosing anemia based on hemoglobin levels.

The study showed considerable differences between the two methods: anemia defined by the standard hemoglobin test was present in 67 percent of subjects, and did not differ based on gender or race. In comparison, using direct blood volume measurement to diagnose anemia, anemia was found in only 35 percent of patients.

The results indicate that with the standard hemoglobin blood testing, there was a doubled increase in overdiagnosis in the studied patient population. Misdiagnosing anemia can lead to an elevated red blood cell count, which could lead to stroke or other medical conditions.

The published research article can be viewed on Daxor’s Website at

For more information visit

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *